患者様やご家族など一般の方向け臨床・治癒情報サイト　臨床研究情報ポータルサイト

ENGLISH
国立保健医療科学院
クリップした情報
×

情報をクリップできます

治験情報をこちらのホームページで一時的にクリップすることが出来ます。

削除
治験例

海外の治験の状況「1」での検索結果

絞り込み

224件の検索結果
  • 進捗状況
  • 試験名
  • 対象疾患名
  • 地域
  • 登録日
  •  

  • Authorised

  • A Phase 1/2 Study of the Safety and Efficacy of CO-1686 in Patients with Previously Treated EGFR Non-Small Cell Lung Cancer
  • Previously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have failed treatment with an EGFR inhibitor such as erlotinib or gefitinib MedDRA version: 19.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864 MedDRA version: 19.0 Level: LLT Classification code 10025048 Term: Lung cancer non-small cell recurrent System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Australia, Poland, United States
  • 2013-03-04

  • Authorised

  • A phase 1/2, open-label, multicenter study, designed to evaluate the safety, tolerability, the blood concentration values and efficacy of a substance called TAS0728.
  • Urothelial cancer with HER2 or HER3 mutation Biliary tract cancer with HER2 or HER3 mutation Breast cancer with HER2 or HER3 mutation Breast cancer with HER2 amplification/overexpression as per ASCO-CAP 2013 guidelines Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Colorectal cancer (CRC) with HER2 mutation or amplification Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial) MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10004593 Term: Bile duct cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10077840 Term: Urothelial cancer of renal pelvis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10079440 Term: Non-squamous non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Australia, France, Spain, United Kingdom, United States
  • 2018-01-17

  • Authorised

  • Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)
  • Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
  • Australia, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hong Kong, Hungary, Italy, Korea, Republic of, Lithuania, Malaysia, New Zealand, Poland, Portugal, Spain, Turkey, United Kingdom, United States
  • 2018-07-30

  • Authorised

  • Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)
  • Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
  • Australia, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom, United States
  • 2018-07-17

  • Authorised

  • A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
  • Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
  • Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
  • 2018-03-02